Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma

被引：0
|
作者：
Bruno, B
Ladetto, M
Mordini, N
Astolfi, M
Rotta, M
Cimolin, L
Compagno, M
Veneziano, L
Aitoro, G
Gallamini, A
Storb, R
Boccadoro, M
机构：
来源：
BONE MARROW TRANSPLANTATION | 2003年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S123 / S124
页数：2
相关论文
共 50 条
  • [21] Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma
    Osman, Keren
    Elliott, Brian
    Mandeli, John
    Scigliano, Eileen
    Malone, Adriana
    Isola, Luis
    Grosskreutz, Celia
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (04) : 249 - 254
  • [22] Advances in minimal residual disease monitoring in multiple myeloma
    Wijnands, Charissa
    Noori, Somayya
    van de Donk, Niels W. C. J.
    VanDuijn, Martijn M.
    Jacobs, Joannes F. M.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2023, 60 (07) : 518 - 534
  • [23] Molecular detection of minimal residual disease in multiple myeloma
    Bai, Yinlei
    Orfao, Alberto
    Sang Chim, Chor
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 11 - 26
  • [24] Autografting followed by non-myeloablative allografting (NST) induces high complete remissions in high risk multiple myeloma.
    Beltrami, G
    Corsetti, MT
    Musto, P
    Carella, AM
    Scalzulli, PR
    Greco, MM
    Lerma, E
    Carella, AM
    BLOOD, 2002, 100 (11) : 622A - 622A
  • [25] Monitoring of minimal residual disease after allografting: A requirement to guide DLI treatment?
    Dazzi, F
    ANNALS OF HEMATOLOGY, 2002, 81 : S29 - S30
  • [26] Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease
    Carella, AM
    Beltrami, G
    Carella, M
    Corsetti, MT
    Scalzulli, RP
    Greco, M
    HAEMATOLOGICA, 2001, 86 (11) : 1121 - 1123
  • [27] Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma
    Qazilbash, MH
    Saliba, R
    Mendoza, F
    Roden, L
    Hosing, C
    Couriel, DE
    Kebriaci, W
    Popat, U
    De Lima, M
    Champlin, RE
    Giralt, SA
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 117 - 117
  • [28] Outpatient allografting using non-myeloablative conditioning: the Mexican experience
    O G Cantú-Rodríguez
    J C Jaime-Pérez
    C H Gutiérrez-Aguirre
    O González-Llano
    C Mancías-Guerra
    L C Tarín-Arzaga
    G J Ruiz-Delgado
    C C Sandoval-Villa
    J Marfil-Rivera
    A Morales-Toquero
    G J Ruiz-Argüelles
    D Gómez-Almaguer
    Bone Marrow Transplantation, 2007, 40 : 119 - 123
  • [29] Outpatient allografting using non-myeloablative conditioning:: the Mexican experience
    Cantu-Rodriguez, O. G.
    Jaime-Perez, J. C.
    Gutierez-Aguirre, C. H.
    Gonzalez-Llano, O.
    Mancias-Guerra, C.
    Tarin-Arzaga, L. C.
    Ruiz-Delgado, G. J.
    Sandoval-Villa, C. C.
    Marfill-Rivera, J.
    Morales-Toquero, A.
    Ruiz-Arguelles, G. J.
    Gomez-Almaguer, D.
    BONE MARROW TRANSPLANTATION, 2007, 40 (02) : 119 - 123
  • [30] Cytofluorimetric monitoring of minimal residual disease can predict clinical remission in multiple myeloma patients undergoing non myeloablative allogeneic transplantation.
    Omede, P
    Bruno, B
    Giaretta, F
    Ladetto, M
    Battaglio, I
    Ruggeri, M
    Di Bello, C
    Morrone, F
    Aitoro, G
    Rotta, M
    Boccadoro, M
    BLOOD, 2002, 100 (11) : 375B - 375B
12345